Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain
- Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine.
- The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis.
- Globally, more than 300 million patients suffer from osteoarthritis. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025.
Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX).
RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme will include more than 1800 patients with knee osteoarthritis who have exhausted available treatment options and still suffer from moderate to severe pain. Grünenthal will conduct three trials across approximately 200 sites across Europe, the US, Latin America, South Africa and Japan to investigate the efficacy and safety of intra-articular injections of RTX in adults. The efficacy endpoints observed in the trials mainly focus on an improvement in the pain and physical function score in the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index from baseline up to 52 weeks. Upon completion, the Phase III programme is intended to enable marketing approval for RTX in the EU, the US, and Japan. Grünenthal aims to submit a new drug application in 2024, leading to a potential market entry of RTX in 2025.
“More than 300 million patients suffer from osteoarthritis1,a progressive disease that currently cannot be cured. They often experience debilitating pain as a result of their condition”, says Jan Adams, Chief Scientific Officer Grünenthal. “We strive to provide these patients with a non-opioid treatment option that combines long-lasting pain relief with a functional improvement of the affected joints.”
“The global osteoarthritis market is expected to grow to approximately $ 11.0 billion in 20252”, says Gabriel Baertschi, Chief Executive Officer, Grünenthal. “Patients are in need for innovative treatment options with better efficacy than current treatments, and without the side-effects of opioids.”
Grünenthal holds the global rights for RTX since the acquisition of the Swiss biotech company Mestex AG in 2021. If the outcome of the Phase III programme is positive, the company intends to explore the potential of RTX for the treatment of osteoarthritis-related pain in additional joints beyond the knee.
RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis. Resiniferatoxin is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This may result in long-lasting pain relief. Initial data shows a long-lasting and significant analgesic effect and functional improvements compared to placebo, as well as a favourable safety profile.
Osteoarthritis (OA) can be defined as a group of distinct but overlapping diseases. They may have different etiologies but similar biological, morphological, and clinical outcomes that affect the articular cartilage, subchondral bone, ligaments, joint capsule, synovial membrane, and periarticular muscles. OA is the most common joint disease in people aged 65 and over. Its etiology is not fully understood, although several related factors include female gender, genetics, metabolism, and excessive mechanical stress. The diagnosis of OA is primarily based on the clinical history and physical examination. The cardinal radiographic features of OA are focal/non-uniform narrowing of the joint space in the areas subjected to the most pressure, subchondral cysts, subchondral sclerosis, and osteophytes.
Osteoarthritis is a joint disease in which the tissues in the joint break down over time. Common symptoms of osteoarthritis include joint pain, stiffness and swelling, as well as changes in how the joint moves and feeling like the joint is loose or unstable. The most commonly affected joints include the knees, hips, hands, neck and lower back. Treatment of osteoarthritis usually includes exercises, maintaining a healthy weight, wearing braces to help with stability, and taking medication, if prescribed. Many patients will ultimately require joint replacement surgery.
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.
More information: www.grunenthal.com
Click here for our Grünenthal Report 2021/2022
Follow us on:
LinkedIn: Grunenthal Group
 Cieza, A., Causey, K., Kamenov, K., Hanson, S. W., Chatterji, S., & Vos, T. (2020). Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10267), 2006-2017.
MarketsAndMarkets Report; Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration (Parenteral), Distribution Channel (Hospital Pharmacies),Purchasing Pattern (Prescription Drugs) - Global Forecast to 2025; 2020. https://www.marketsandmarkets.com/Market-Reports/osteoarthritis-therapeutics-market-209565994.html
 National Institute of Arthritis and Musculoskeletal and Skin Diseases; What Causes Osteoarthritis, Symptoms & More | NIAMS (nih.gov)
Communication Business Partner
Phone: +49 241 569-1428
Head Global Communication
Phone: +49 241 569-2555
About news aktuell GmbH
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Kreisel Electric to expand battery production capacities to over 2 GWh22.9.2022 10:10:48 CEST | Press release
Rainbach im Mühlkreis - Deere & Company (NYSE: DE) announced its next steps in meeting the growing demand for batteries as a sole- or hybrid-propulsion system. In addition to the production facility in Austria, John Deere is making an immediate investment in two additional locations to increase the production capacity expansion of Kreisel Electric (“Kreisel”) — the battery technology pioneer in which John Deere recently acquired majority ownership. The significant capital commitment will bring an increase of over 2 GWh to Kreisel battery production capacity, beginning with the opening of a new facility at the John Deere Saran factory — the primary manufacturing location for John Deere engines in the European Union. In parallel with this project, John Deere will also invest in battery assembly in the United States to support the growth of its customers and John Deere products. Find more information here: Kreisel Press Area
TXOne Networks and Valmet to expand their successful OT/ICS cybersecurity services partnership22.9.2022 09:45:00 CEST | Press release
Eindhoven/Tampere, September 22, 2022 — TXOne Networks, a global leader in ICS and industrial IoT (IIoT) security, and Valmet, a leading global developer and supplier of process technologies, automation and services for the pulp, board, paper, tissue, nonwovens, energy, marine and process industries, have announced a partnership. Together they will better equip joint industrial automation customers with the protection they need for today’s vulnerable OT (Operational Technology) environments. The combination of TXOne Networks’s solutions for security inspection, endpoint protection and network defenses with the leading Valmet DNA Distributed Control System (DCS), Valmet IQ Quality Control System (QCS), Machine Vision, Analyzers & Measurements, Valves and Industrial Internet, offers various advantages: It enhances the ability of industrial customers to better protect, respond, and recover from a cybersecurity incident with Valmet’s Cybersecurity Services. As Dr. Terence Liu, CEO of TXOne
China's growing photovoltaic industry may become the preferred choice of the European and American markets21.9.2022 10:33:04 CEST | Press release
Frankfurt, Germany - In the context of climate change, energy crisis and recurring epidemics, the world attaches great importance to sustainable development and low-carbon energy transformation. Driven by breakthroughs of renewable energy and policy tools, the global photovoltaic market maintains a good development trend. In recent years, China's photovoltaic industry has become an important player in the global photovoltaic industry. For the global market, the choice of China's PV supply chain is an extremely favorable move. Insiders believe that the essence of building a community of human destiny can be summarized by "national interests and common prosperity". Countries across the world should deeply understand that their destinies are closely linked to each other, so as to promote mutually beneficial cooperation, give full play to their own advantages, jointly make a larger cooperation cake, and guarantee the right of all countries to pursue prosperity and development. In recent ye
Minister of Economy Heads UAE’s Delegation to Greece with Extensive Government & Private-Sector Participation The UAE Country of Honor at Thessaloniki International Fair TIF 869.9.2022 07:54:08 CEST | Pressmeddelande
Abu Dhabi – 07/09/2022
Last chance to enter “BEAUTY FUTURES” –The DOUGLAS’ start-up competition8.9.2022 12:32:57 CEST | Press release
Applications accepted until September 19 on www.douglasbeautyfutures.com Nominations in three categories: Beauty & Health Product Innovation, Beauty & Health Digital Solution, Sustainability Innovation The winners’ creations may be added to the DOUGLAS product range Highly respected jury members, including DOUGLAS Group CEO Tina Müller and leading experts a.o. Lea-Sophie Cramer, Sara Nuru, Tijen Onaran and Philipp Westermeyer Düsseldorf, 08. September 2022. The countdown is on: Start-ups in the beauty and health industry can still apply for BEAUTY FUTURES –The DOUGLAS Start-up Challenge. Until September 19 applicants can submit a description of their idea, a pitch deck and a video on the BEAUTY FUTURES website to get the chance to work with Europe’s leading premium beauty & health platform. DOUGLAS is searching for unique products or services in three categories: Beauty & Health Product Innovationfocuses on innovative beauty and health products such as skincare, make-up, fragrance, hai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom